BIOBV logo

Biohit Oyj Stock Price

Symbol: HLSE:BIOBVMarket Cap: €47.1mCategory: Healthcare

BIOBV Share Price Performance

€3.10
0.72 (30.25%)
€3.10
0.72 (30.25%)
Price €3.10

BIOBV Community Narratives

There are no narratives available yet.

BIOBV Community Fair Values

    Recent BIOBV News & Updates

    No updates

    Biohit Oyj Key Details

    €14.3m

    Revenue

    €4.9m

    Cost of Revenue

    €9.3m

    Gross Profit

    €6.8m

    Other Expenses

    €2.6m

    Earnings

    Last Reported Earnings
    Dec 31, 2024
    Next Reporting Earnings
    Aug 06, 2025
    Earnings per share (EPS)
    0.17
    Gross Margin
    65.39%
    Net Profit Margin
    17.98%
    Debt/Equity Ratio
    0%

    Biohit Oyj Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About BIOBV

    Founded
    1988
    Employees
    46
    CEO
    Jussi Hahtela
    WebsiteView website
    www.biohithealthcare.com

    Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vitamin D, a test for determination of 25-hydroxyvitamin D2 and D3; and BIOHIT Calprotectin test, a quantitative test that provides a reliable differentiation between inflammatory bowel diseases and irritable bowel syndrome. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H. Pylori) and atrophic gastritis; BIOHIT Celiac Quick test for diagnosis of celiac disease; Biohit ColonView Quick test, a test for detection of fecal occult blood; Biohit Helicobacter Pylori UFT300 and Helicobacter Pylori Quick test methods to detect H. pylori infection; Gluten Immunogenic Peptides test; and Lactose Intolerance quick test to support the diagnosis of lactose intolerance in a duodenal biopsy specimen. The company provides acetaldehyde-binding products, such as Acetium capsules for protection of stomach; Acetium lozenge, which helps in quitting smoking; and monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. It also offers BIOHIT FAEX for the collection and handling of stool samples; and GP Reader NT, an automated instrument for the quantitative determination of various analytes in human samples, such as whole blood, plasma, or fecal samples by measuring fluorescence signals from lateral flow test cassettes. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

    Finnish Market Performance

    • 7 Days: -2.2%
    • 3 Months: 4.6%
    • 1 Year: 11.2%
    • Year to Date: 9.2%
    Over the last 7 days, the market has dropped 2.2%, driven by a loss of 6.9% in the Materials sector. In the last year, the market is actually up 11%. Earnings are forecast to grow by 16% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading